Evidence map›Paper›PMID 35563144›Full record

ReviewInternational journal of molecular sciences2022

Sclerostin: From Molecule to Clinical Biomarker.

Ahmed Omran, Diana Atanasova, Filip Landgren, Per Magnusson

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Prognostic value of serum estradiol and sclerostin for predicting fracture healing in postmenopausal women with osteoporotic vertebral compression fractures.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ahmed OmranDepartment of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 85 Linköping, Sweden.ORCID 0000-0002-1997-8960
Diana AtanasovaDepartment of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 85 Linköping, Sweden.
Filip LandgrenDepartment of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 85 Linköping, Sweden.
Per MagnussonDepartment of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 85 Linköping, Sweden.ORCID 0000-0002-2123-7838
Linköping University · SE

Funding

ALF Grants from Region Östergötland RÖ-962532
6 · The paper itself

Abstract

Sclerostin, a glycoprotein encoded by the

Indexed as

Intercellular Signaling Peptides and ProteinsMechanotransduction, CellularAdaptor Proteins, Signal TransducingBiomarkersFemaleHumansMaleOsteocytesWnt Signaling PathwayAdaptor Proteins, Signal TransducingBiomarkersIntercellular Signaling Peptides and Proteinsbonebone formationimmunoassayLRP6mechanotransductionosteocytereference intervalSOSTWnt signalingβ-catenin

Identifiers

PMID35563144
PMCPMC9104784
OpenAlexW4225015870

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.